Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Altimmune (NASDAQ: ALT ) is approaching a pivotal moment in 2025, one that could redefine its future. I believe Altimmune offers a compelling risk-reward profile, and as such, I am long the stock - mindful of the inherent risks tied to thisHelixberg is an independent biotech publication dedicated to providing concise and insightful briefings on major biotech catalysts and portfolio strategies. As a seasoned healthcare professional with extensive experience in the biotech sector and hedge fund industry, I fo ...